To prepare for clinical trials Fusion have recruited Dr Nigel Courtenay-Luck as Director of Clinical Development.

Nigel co-founded Antisoma Research Ltd in 1988 has been a pioneer/leader in the cancer antibody-therapeutic field for over twenty years. In this period he has been involved in bringing several antibodies into all stages of clinical trials, from phase I to phase III. Nigel is an honourey senior lecturer in the Division of Medicine at Hammersmith Hospital  and a Fellow of the Royal Society of Medicine. Nigel has collaborated with many of the worlds leading cancer centers, such as the MD Anderson and the Medical University of South Carolina (MUSC), where he has collaborated on both scientific and clinical research for several years. We are delighted that Nigel will also join the board as a non-executive director.